肝硬化临床终点事件的精准预测

周家玲; 尤红

doi:10.3969/j.issn.1001-5256.2020.09.001

肝硬化临床终点事件的精准预测

DOI: 10.3969/j.issn.1001-5256.2020.09.001

周家玲,
尤红

首都医科大学附属北京友谊医院肝病中心

基金项目:

国家科技重大专项(2018ZX10302204-001,2018ZX10302204-004,2018ZX09201016-001)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1297
- HTML全文浏览量: 27
- PDF下载量: 307
- 被引次数: 0
出版历程
- 收稿日期: 2020-05-07
- 出版日期: 2020-09-20

Accurate prediction of clinical endpoints of liver cirrhosis

Liver Research Center,Beijing Friendship Hospital,Capital Medical University

Research funding:

摘要

摘要: 尽管根据病因治疗已经降低肝硬化并发症的发生率和病死率,但部分患者仍会出现疾病进展。实现肝硬化临床终点事件的精准预测并加强干预对于进一步降低病死率至关重要。为此,从肝组织病理学、无创性指标、影像学及方法学等方面共同探讨对肝硬化临床终点事件的预测,以提早筛选高风险人群,建立精准预测模型,帮助进一步减少肝硬化临床终点事件的发生。
- 肝硬化 /
- 预后 /
- 精准预测
Abstract: Although etiological treatment has reduced the incidence and mortality rates of liver cirrhosis complications,some patients may still experience disease progression. It is of great importance for further reducing mortality rate to accurately predict the clinical endpoints of liver cirrhosis and strengthen intervention. Therefore,this article discusses the prediction of clinical endpoints of liver cirrhosis from the aspects of liver pathology,noninvasive markers,imaging,and methodology,in order to help with early screening of the high-risk population,establish accurate predictive models,and further reduce the incidence rate of clinical endpoints of liver cirrhosis.
- liver cirrhosis /
- prognosis /
- precise prediction

HTML全文

参考文献(13)

[1] SHIM JJ,OH CH,KIM JW,et al. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy[J]. Scand J Gastroenterol,2017,52(9):1029-1036.

[2] GOODMAN ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases[J]. J Hepatol,2007,47(4):598-607.

[3] SUN Y,ZHOU J,WU X,et al. Quantitative assessment of liver fibrosis(qFibrosis)reveals precise outcomes in Ishak “stable”patients on anti-HBV therapy[J]. Sci Rep,2018,8(1):2989.

[4] KIM SU,JUNG KS,LEE S,et al. Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma[J]. Liver Int,2014,34(7):1008-1017.

[5] WU S,KONG Y,PIAO H,et al. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis[J]. Liver Int,2018,38(6):1045-1054.

[6] KONG Y,SUN Y,ZHOU J,et al. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir[J]. J Viral Hepat,2019,26(5):576-585.

[7] QI X,AN W,LIU F,et al. Virtual hepatic venous pressure gradient with CT angiography(CHESS 1601):A prospective multicenter study for the noninvasive diagnosis of portal hypertension[J]. Radiology,2019,290(2):370-377.

[8] VILLANUEVA C,ALBILLOS A,GENESCJ,et al．βblockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension(PREDESCI):A randomised,double-blind,placebo-controlled,multicentre trial[J].Lancet,2019,393(10181):1597-1608.

[9] GRADY D,BERKOWITZ SA. Why is a good clinical prediction rule so hard to find?[J]. Arch Intern Med,2011,171(19):1701-1702.

[10] TANGRI N,KENT DM. Toward a modern era in clinical prediction:The TRIPOD statement for reporting prediction models[J]. Am J Kidney Dis,2015,65(4):530-533.

[11] PAPATHEODORIDIS GV,CHAN HL,HANSEN BE,et al. Risk of hepatocellular carcinoma in chronic hepatitis B:Assessment and modification with current antiviral therapy[J]. J Hepatol,2015,62(4):956-967.

[12] WONG GL,CHAN HL,WONG CK,et al. Liver stiffnessbased optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B[J]. J Hepatol,2014,60(2):339-345.

[13] KIM JH,KIM YD,LEE M,et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy[J]. J Hepatol,2018,69(5):1066-1073.

施引文献

资源附件(0)

访问统计